专利检索 ap:("Jef Fenscholdt" OR "Thomas Høyer" OR "Xifu Liang" OR "Sophie Elisabeth Havez") AND inv:"Sophie Elisabeth Havez" 第 1 页

1.

发明申请
CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS 审中-公开
标题翻译：钙敏感受体活性化合物

公开(公告)号：US20120101039A1

公开(公告)日：2012-04-26

申请号：US13322189

申请日：2010-05-26

申请人： Jef Fenscholdt , Thomas Høyer , Xifu Liang , Sophie Elisabeth Havez

发明人： Jef Fenscholdt , Thomas Høyer , Xifu Liang , Sophie Elisabeth Havez

IPC分类号： A61K38/23 , A61K31/24 , C07C63/36 , A61K31/195 , C07D295/10 , A61K31/5375 , C07D211/62 , A61K31/445 , C07D315/00 , A61K31/351 , A61K31/59 , A61P25/28 , A61P3/00 , A61P19/00 , A61P5/00 , A61P19/10 , A61P1/00 , C07C69/76

CPC分类号： C07D295/088 , C07C217/62 , C07C229/34 , C07C229/38 , C07C237/20 , C07C237/36 , C07D205/04 , C07D211/66 , C07D307/33 , C07D309/06 , C07D309/08 , C07D405/06

摘要： A compound of general formula I their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, methods of treating diseases with said compounds, and the use of said compounds in the manufacture of medicaments.

摘要翻译： 通式I的化合物，其用作钙受体活性化合物用于预防，治疗或改善与CaSR活性紊乱相关的生理障碍或疾病，例如甲状旁腺功能亢进，包含所述化合物的药物组合物，用所述化合物治疗疾病的方法，以及所述化合物在制备药物中的用途。

2.

发明申请
SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES 审中-公开
标题翻译：替代乙酰化合物可用于治疗疾病

公开(公告)号：US20100279936A1

公开(公告)日：2010-11-04

申请号：US12376417

申请日：2007-08-16

申请人： Xifu Liang , Thomas Høyer , Jef Fensholdt , Sophie Elisabeth Havez , Bjarne Nørremark

发明人： Xifu Liang , Thomas Høyer , Jef Fensholdt , Sophie Elisabeth Havez , Bjarne Nørremark

IPC分类号： A61K38/23

CPC分类号： C07D213/40 , C07B2200/07 , C07C211/29 , C07C211/30 , C07C211/49 , C07C215/24 , C07C215/28 , C07C215/30 , C07C215/50 , C07C215/54 , C07C217/46 , C07C217/58 , C07C217/62 , C07C229/30 , C07C229/34 , C07C229/38 , C07C233/36 , C07C233/38 , C07C233/62 , C07C235/10 , C07C235/60 , C07C237/16 , C07C255/30 , C07C255/58 , C07C271/20 , C07C275/24 , C07C275/26 , C07C275/28 , C07C275/30 , C07C275/34 , C07C311/05 , C07C311/18 , C07C311/29 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07D207/12 , C07D209/08 , C07D211/46 , C07D211/58 , C07D211/62 , C07D231/12 , C07D263/32 , C07D295/13 , C07D295/182 , C07D309/08 , C07D309/10 , C07D317/28 , C07D317/58 , C07D333/20 , C07D333/58 , C07F7/081 , C07F7/1804

摘要： The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C1-10heteroaryl, C6-14aryl or C6-10heterocycloalkylaryl; R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6hydroxyalkyl, C1-6haloalkyl, C1-6amino, C3-6 cycloalkyl, or C1-6heterocycloalkyl, each of which are optionally substituted; X represents —CR3R4—(CR5R6)n—(CR7═CR8)m—(C6-14aryl)r-(C1-10heteroaryl)s-(CR9R10)p—(CR11═CR12)q, R2 represents C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6hydroxyalkyl, C1-6haloalkyl, C1-6amino, C1-12alkylsilyl, C6-30alkylarylsilyl, C1-10heteroaryl, C6-14aryl, C1-10heterocycloalkyl, C1-10heterocycloalkenyl, C1-8cycloalkyl, C1-18cycloalkenyl, each of which is optionally substituted, or R2 represents hydrogen, carboxy, or hydroxy; or a pharmaceutically acceptable salt, solvate, or ester thereof; to processes for the preparation thereof, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, wherein said compounds being useful, e.g. in the treatment of diseases associated with disturbances of CaSR activity, such as hyperparathyroidism.

摘要翻译： 本发明涉及根据式Ia和Ib的新化合物; （式Ia和Ib）其中A表示取代或未取代的C1-10杂芳基，C6-14芳基或C6-10杂环烷基芳基; R 1是C 1-6烷基，C 2-6烯基，C 2-6炔基，C 1-6羟基烷基，C 1-6卤代烷基，C 1-6氨基，C 3-6环烷基或C 1-6杂环烷基，其各自任选被取代; X表示-CR3R4-（CR5R6）n-（CR7 = CR8）m-（C6-14芳基）r-（C1-10杂芳基）s-（CR9R10）p-（CR11 = CR12）q，R2表示C1-6烷基，C2 6-烯基，C 2-6炔基，C 1-6羟基烷基，C 1-6卤代烷基，C 1-6氨基，C 1-12烷基甲硅烷基，C 6-30烷基芳基甲硅烷基，C 1-10杂芳基，C 6-14芳基，C 1-10杂环烷基，C 1-10杂环烯基，C 1-8环烷基，，其各自任选被取代，或R 2表示氢，羧基或羟基; 或其药学上可接受的盐，溶剂化物或酯; 涉及用于制备其的所述化合物，用于治疗的所述化合物，包含所述化合物的药物组合物，其中所述化合物是有用的。治疗与CaSR活动相关的疾病，如甲状旁腺功能亢进。